D.C.’s Vanda Pharmaceuticals Inc. has locked in a deal with a West Coast biotech to commercialize a drug for a rare skin ...

Vanda Pharmaceuticals and AnaptysBio announced an exclusive, global license agreement for the development and commercialization of imsidolimab.

Vanda Pharmaceuticals (VNDA) and AnaptysBio (ANAB) announced an exclusive, global license agreement for the development and commercialization ...

Vanda expects to immediately begin preparing BLA and MAA applications for the U.S. and EU.

Imsidolimab has successfully completed two global Phase 3 studies in Generalized Pustular PsoriasisVanda expects to immediately begin preparing ...

H.C. Wainwright maintained a Buy rating on Vanda Pharmaceuticals (NASDAQ:VNDA) with a price target of $18.00, representing significant upside potential from the current price of $4.31. According to ...

Vanda Pharmaceuticals and AnaptysBio have announced an exclusive worldwide licence agreement to develop and commercialise the ...

Following the agreement, Vanda is preparing BLA and MAA applications for the US and EU, with a focus on commercialization. Imsidolimab, a fully humanized IgG4 antibody, is expected to provide ...

Immersive exhibition reimagines art through multi-sensory experience to improve the accessibility of visual arts for those with visual impairments.Blending technology, innovation, and creativity, ...

With a plan to expand its pharmaceutical solutions arm, St. Pete-based engineering and manufacturing giant Jabil recently secured a deal to acquire Pharmaceutics International Inc.